ARTHROPLASTY, REPLACEMENT Clinical Trial
Official title:
Patient-Centered Weight Loss Program for Knee Replacement Patients
PACE is a patient-centered weight loss program that was developed specifically for knee replacements based on input from stakeholders, including knee replacement patients, physical therapists, and orthopedic surgeons. In this pilot study, participants undergoing knee replacement will be randomized to either start a weight loss program before surgery (PACE) or after surgery (Delayed PACE). Both programs will receive a 14-week intervention and complete assessments at baseline (up to 6 weeks prior to surgery), 12 weeks after surgery, and 26 weeks after surgery.
It is estimated that half of patients diagnosed with knee osteoarthritis (OA) will need a total knee replacement (TKR) during their lifetime. Of patients who need a TKR, 80-95% are overweight or obese. While patients are encouraged to lose weight, limited, if any, guidance is provided to achieve recommended weight loss. Many patients perceive that TKR is a necessary precursor for the initiation of weight loss. Yet, 66% of patients actually gain weight by 2 years after surgery. Patients undergoing TKR not only face unique barriers (i.e., pain, mobility limitations, motivation) to weight loss, but also have to balance pre- and post-operative concerns from physicians, surgeons, and rehabilitation specialists. To best accommodate the needs of both patients (pre- and post-TKR) and healthcare professionals (i.e., surgeon, physical therapist), patient and stakeholder engagement and activation is imperative in the development of a patient-centered weight loss intervention. Investigators completed 20 interviews with patients pre- and post-TKR and identified weight loss barriers, preferred intervention components (e.g., delivery method, contact frequency, self-monitoring modality) and patient-reported outcomes (e.g., physical function, pain) viewed as critical by patients. Investigators developed a patient-centered weight loss program (PACE) guided by these results and additional input from stakeholders to meet the needs of patients and healthcare professionals. PACE is a randomized pilot study comparing weight loss and patient-reported outcomes between PACE (program starting up to 6 weeks pre-TKR to 12 weeks post-TKR) and Delayed PACE (program starting 12 weeks post-TKR to 26 weeks post-TKR). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04080401 -
Effectiveness of a Novel Gaming System on Post-operative Rehabilitation Outcomes After Total Knee Arthroplasty
|
N/A | |
| Completed |
NCT02648958 -
Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations
|
N/A | |
| Completed |
NCT00846807 -
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
|
N/A | |
| Completed |
NCT04372173 -
An Evaluation of Clotting Factor Activity Before and After Total Hip Arthroplasty
|
||
| Recruiting |
NCT01909375 -
American Joint Replacement Registry
|
||
| Terminated |
NCT01153698 -
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
|
||
| Completed |
NCT01184989 -
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
|
Phase 4 | |
| Active, not recruiting |
NCT00114036 -
Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)
|
N/A | |
| Completed |
NCT03407885 -
The Impact of Medicare Bundled Payments
|
N/A | |
| Completed |
NCT01857349 -
Efficacy of Surgical Preparation Solutions in Knee Surgery
|
N/A | |
| Completed |
NCT00847301 -
Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
|
N/A | |
| Recruiting |
NCT04697004 -
SMR Stemless Reverse vs SMR Reverse Shoulder System
|
N/A | |
| Completed |
NCT03158623 -
Wound Additives in Primary Total Joint Athroplasty
|
Phase 3 |